Treatment rationale and study de-sign for the pointbreak study:a randomized,open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by mainte-nance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevaci-zumab followed by maintenance bevacizumab in patients with stage II-IB or IV nonsquamous non-small-cell lung cancer

查看全文 作　　者：Patel JD;Bonomi P;Socinski MA;Govindan R;Hong S;Obasaju C;Pennella EJ;Girvan AC;Guba SC